His industrial career started at The Upjohn Company in 1982, where he was responsible for Phase I and Phase II Clinical Development of several cancer drug candidates, as well as a Named Patient program for irinotecan. This was followed by 5 years with the Oncology Medical Affairs group at Rhône-Poulenc Rorer in Collegeville, PA, during which period several hundred Investigator-Sponsored Trials for docetaxel were initiated in the US.
> more